Accelerate diagnosis. Address antimicrobial resistance.
Addressing two growing global healthcare challenges: early infection diagnosis and antimicrobial resistance, the promise of our technology is to transform patient care pathways. Rapid, reliable information about the presence of infection is not available with current diagnostic techniques. This costs money, time, and resources and leads to loss of life.
Our first product: ruling out infection with 95% accuracy
InfectiClear® will be our first product to market – an accurate, reliable blood test that rules out infection faster and more accurately than diagnostic techniques currently available. InfectiClearTM has been selected for the pioneering Innovative Devices Access Pathway programme in the UK.
Our products are developed using machine learning with real-world patient data.
Our unique clinical metadata is derived from around 150,000 samples and seven studies, using machine learning to extract insights and develop pioneering assays.
Global Perspective:
What the experts say.
Fueling Progress:
Our Investors and Tech Collaborators
Offering expertise and resources, our investors and tech collaborators are critical in the evolution of Presymptom Health.